Sustained Response to Brigatinib in an Aggressive Relapsing Atypical Pituicytoma With ELM4-ALK Fusion.
作者信息
Moser Pierre-Olivier, Rigau Valérie, Goze Catherine, Ringeard Isabelle, Favier Valentin, Darlix Amélie, Boetto Julien
机构信息
Department of Neurosurgery, Gui-De-Chauliac Hospital, Montpellier University Medical Center, Montpellier, France.
Department of Pathology, Gui-De-Chauliac Hospital, Montpellier University Medical Center, Montpellier, France.
出版信息
JCO Precis Oncol. 2024 Nov;8:e2400381. doi: 10.1200/PO-24-00381. Epub 2024 Nov 22.
Abstract
摘要
相似文献
1
Sustained Response to Brigatinib in an Aggressive Relapsing Atypical Pituicytoma With ELM4-ALK Fusion.对具有ELM4-ALK融合的侵袭性复发性非典型垂体细胞瘤使用布吉他滨的持续反应。
JCO Precis Oncol. 2024 Nov;8:e2400381. doi: 10.1200/PO-24-00381. Epub 2024 Nov 22.
2
Efficacy of Brigatinib in Patients With Advanced ALK-Positive NSCLC Who Progressed on Alectinib or Ceritinib: ALK in Lung Cancer Trial of brigAtinib-2 (ALTA-2).布加替尼在阿来替尼或塞瑞替尼治疗后进展的晚期 ALK 阳性 NSCLC 患者中的疗效：brigAtinib-2（ALTA-2）用于治疗肺癌的 ALK 试验。
J Thorac Oncol. 2022 Dec;17(12):1404-1414. doi: 10.1016/j.jtho.2022.08.018. Epub 2022 Sep 10.
3
Primary Resistance to Brigatinib in a Patient with Lung Adenocarcinoma Harboring G1202R Mutation and Rearrangement.一名携带G1202R突变和重排的肺腺癌患者对布加替尼的原发性耐药
Onco Targets Ther. 2020 May 22;13:4591-4595. doi: 10.2147/OTT.S249652. eCollection 2020.
4
Brigatinib Versus Alectinib in ALK-Positive NSCLC After Disease Progression on Crizotinib: Results of Phase 3 ALTA-3 Trial.布加替尼对比阿来替尼用于克唑替尼治疗后进展的 ALK 阳性 NSCLC ：III 期 ALTA-3 试验结果。
J Thorac Oncol. 2023 Dec;18(12):1743-1755. doi: 10.1016/j.jtho.2023.08.010. Epub 2023 Aug 12.
5
Repurposing Brigatinib for the Treatment of Colorectal Cancer Based on Inhibition of ER-phagy.基于抑制内质网自噬的 brigatinib 再利用治疗结直肠癌。
Theranostics. 2019 Jul 9;9(17):4878-4892. doi: 10.7150/thno.36254. eCollection 2019.
6
Brigatinib in the first-line treatment of ALK+ metastatic NSCLC: safety and efficacy.布加替尼在 ALK+转移性 NSCLC 一线治疗中的安全性和疗效。
Expert Rev Anticancer Ther. 2021 Aug;21(8):809-817. doi: 10.1080/14737140.2021.1923485. Epub 2021 May 13.
7
Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial.布加替尼与克唑替尼用于初治的晚期ALK阳性非小细胞肺癌：3期ALTA-1L试验的最终结果
J Thorac Oncol. 2021 Dec;16(12):2091-2108. doi: 10.1016/j.jtho.2021.07.035. Epub 2021 Sep 16.
8
Brigatinib treatment in a patient with advanced NSCLC with XPO1-ALK fusion: a case report.布加替尼治疗1例晚期非小细胞肺癌伴XPO1-ALK融合患者：病例报告
Front Oncol. 2025 Jan 22;14:1503262. doi: 10.3389/fonc.2024.1503262. eCollection 2024.
9
Exceptional response to brigatinib following alectinib failure in a patient with fusion-positive duodenal carcinoma.在一名伴有 融合阳性十二指肠癌的患者中，阿来替尼治疗失败后布加替尼取得显著疗效。
Int Cancer Conf J. 2025 Feb 10;14(2):131-135. doi: 10.1007/s13691-025-00745-2. eCollection 2025 Apr.
10
Brigatinib in Japanese patients with ALK-positive non-small-cell lung cancer: Final results of the phase 2 J-ALTA trial.布加替尼在日本 ALK 阳性非小细胞肺癌患者中的疗效：Ⅱ期 J-ALTA 试验的最终结果。
Cancer Sci. 2023 Sep;114(9):3698-3707. doi: 10.1111/cas.15888. Epub 2023 Jul 11.
本文引用的文献
1
High efficacy of brigatinib for brain metastases in ALK fusion gene-positive non-small cell lung cancer: A case series.ALK 融合基因阳性非小细胞肺癌脑转移的布加替尼高疗效：病例系列。
Thorac Cancer. 2024 Feb;15(6):496-499. doi: 10.1111/1759-7714.15207. Epub 2023 Dec 30.
2
ALK Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma.ALK 扩增和重排是先天性和成人胶质母细胞瘤中反复出现的靶向治疗事件。
Clin Cancer Res. 2023 Jul 14;29(14):2651-2667. doi: 10.1158/1078-0432.CCR-21-3521.
3
Genetic and epigenetic characterization of posterior pituitary tumors.后垂体肿瘤的遗传和表观遗传特征。
Acta Neuropathol. 2021 Dec;142(6):1025-1043. doi: 10.1007/s00401-021-02377-1. Epub 2021 Oct 18.
4
Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial.布加替尼与克唑替尼用于初治的晚期ALK阳性非小细胞肺癌：3期ALTA-1L试验的最终结果
J Thorac Oncol. 2021 Dec;16(12):2091-2108. doi: 10.1016/j.jtho.2021.07.035. Epub 2021 Sep 16.
5
Two challenging cases of pituicytoma.两例具有挑战性的垂体瘤病例报告。
Hormones (Athens). 2021 Dec;20(4):813-818. doi: 10.1007/s42000-021-00301-6. Epub 2021 Aug 14.
6
Skull Base Tumors: Neuropathology and Clinical Implications.颅底肿瘤：神经病理学与临床意义。
Neurosurgery. 2022 Mar 1;90(3):243-261. doi: 10.1093/neuros/nyab209. Epub 2021 Nov 24.
7
Clinical-Pathological, Immunohistochemical, and Genetic Characterization of a Series of Posterior Pituitary Tumors.一系列垂体后叶肿瘤的临床病理、免疫组织化学及遗传学特征
J Neuropathol Exp Neurol. 2021 Jan 1;80(1):45-51. doi: 10.1093/jnen/nlaa139.
8
Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial.布加替尼与克唑替尼用于初治的ALK 阳性非小细胞肺癌：III 期 ALTA-1L 试验的第二次期中分析。
J Clin Oncol. 2020 Nov 1;38(31):3592-3603. doi: 10.1200/JCO.20.00505. Epub 2020 Aug 11.
9
Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable Outcomes.婴儿高级别神经胶质瘤包含多个亚组，其特征为新型可靶向基因融合和良好的预后。
Cancer Discov. 2020 Jul;10(7):942-963. doi: 10.1158/2159-8290.CD-19-1030. Epub 2020 Apr 1.
10
Primary tumors of the posterior pituitary: A systematic review.鞍区原发性肿瘤：系统综述。
Rev Endocr Metab Disord. 2019 Jun;20(2):219-238. doi: 10.1007/s11154-019-09484-1.
Zotero 插件